Chemoinformaics analysis of 3-Ethyl-2,5-dimethylpyrazine
| Molecular Weight | 136.198 | nRot | 1 |
| Heavy Atom Molecular Weight | 124.102 | nRig | 0 |
| Exact Molecular Weight | 136.1 | nRing | 1 |
| Solubility: LogS | -7.327 | nHRing | 1 |
| Solubility: LogP | 9.64 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 22 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 10 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 12 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 8 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 6 |
| nHA | 2 | APOL | 23.5615 |
| nHD | 0 | BPOL | 14.3185 |
| QED | 0.252 |
| Synth | 1.068 |
| Natural Product Likeliness | 0.129 |
| NR-PPAR-gamma | 0.075 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0 |
| Pgp-sub | 0 |
| HIA | 0.002 |
| CACO-2 | -4.92 |
| MDCK | 0.00000671 |
| BBB | 0.049 |
| PPB | 0.984199 |
| VDSS | 4.189 |
| FU | 0.013967 |
| CYP1A2-inh | 0.137 |
| CYP1A2-sub | 0.173 |
| CYP2c19-inh | 0.286 |
| CYP2c19-sub | 0.064 |
| CYP2c9-inh | 0.07 |
| CYP2c9-sub | 0.956 |
| CYP2d6-inh | 0.269 |
| CYP2d6-sub | 0.043 |
| CYP3a4-inh | 0.182 |
| CYP3a4-sub | 0.034 |
| CL | 4.467 |
| T12 | 0.04 |
| hERG | 0.279 |
| Ames | 0.007 |
| ROA | 0.028 |
| SkinSen | 0.96 |
| Carcinogencity | 0.029 |
| EI | 0.933 |
| Respiratory | 0.443 |
| NR-Aromatase | 0.066 |
| Antiviral | No |
| Prediction | 0.91396 |